Galectin Therapeutics Inc. Warrants (GALTW)

[biotech2010]

Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis

http://ih.advfn.com/p.php?pid=nmona&article=63031552

You never know how the market will react to trial results but the most interesting part of this announcement is the reference to the use of Fibroscan in analyzing the data-if GALT didn't think the results were promising this would not have been in the press release (nor the reference to its use in a Phase 2 trial).

I've had this stock for over 5 years and have complete confidence in both the management team and the drug, we'll have to see how the market reacts to the results on Tuesday for the short term but long term they continue to be on course for a multi-billion dollar market cap company, probably at the conclusion of the Phase 2 trial for GR-MD-02.